Sana has emerged with funding from investors including F-Prime Capital, Arch and Flagship Pioneering to develop genetically modified hypoimmogenic stem cells.

Hookipa Pharma, a Boehringer Ingelheim, Takeda and Gilead-backed infectious disease and cancer drug developer, has filed for an $86.3m IPO.

The firm posted its half-year results for the period ending December 2018, registering an 83% year-on-year rise in turnover and a 43% gain in the fair value of its portfolio.

Roche Venture Fund was among the existing investors that helped supply $50m for Arch Oncology, the cancer drug developer formerly known as Tioma.

The Mitsui-backed glucose monitoring technology provider will use the series E proceeds to fund the commercialisation of its device in the US.

The university will benefit from a hub to house its AI and biomedical research in addition to co-working space and a think-tank targeting the ethics of emerging technologies.

NetScientific has exited its loss-making portfolio companies Vortex and Wanda after originally deciding to close the two medical diagnostics ventures last week.

GreenMark’s dental treatments will be developed in partnership with University of Michigan, which has backed the company’s two-tranche seed round through its Mints Fund.

The firm’s portfolio fell to a $61.8m net loss during 2018 amid difficult market conditions for listed small-cap businesses and the consolidation of its former peer Touchstone Innovations.

Perspectives on sustainability and wellbeing are changing in response to health and environmental challenges, offering an opportunity to university-linked businesses.